Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Omics-guided therapy reshapes advanced prostate cancer care

A review of omics-guided strategies in advanced prostate cancer examines biomarkers, DDR alterations, and precision therapy development.

By Dr. Revathy Mohan V.R., MBBS · Oct 23, 2026 · 5 min read

Oncology·JCO

Adjuvant Breast Cancer Care Models Expand Capacity in Canada

Canadian centers outline multidisciplinary models to support adjuvant treatment, monitoring, and adherence in HR-positive, HER2-negative early breast cancer.

Oct 23, 2026

Oncology·JCO

Frailty and Unmet Social Needs Converge in Cancer Care

ASCO commentary examines how frailty and unmet health-related social needs intersect, shaping vulnerability, treatment tolerance, and care planning.

Oct 23, 2026

Oncology·JCO

Platinum-Resistant Ovarian Cancer Review Details ADCs and New Combinations

A JCO review examines antibody-drug conjugates, resistance mechanisms, and emerging combination strategies in platinum-resistant ovarian cancer.

Oct 23, 2026

Oncology·JCO

PROSTest mRNA Assay Tracks Early Response to 177LuPSMA Therapy

Early shifts in the blood-based PROSTest mRNA assay may help predict outcomes with 177LuPSMA radioligand therapy and chemotherapy…

Oct 23, 2026

Oncology·JCO

Radiation Therapy Strategies Are Reframing Unresectable LA-NSCLC Care

A narrative review examines radiation therapy intensification, de-escalation, and organ-sparing techniques for unresectable locally advanced NSCLC.

Oct 23, 2026

Oncology·JCO

First-in-Human 211At-CD45 Radioimmunotherapy Enters Transplant Conditioning

A first-in-human study examines 211At-CD45 radioimmunotherapy with nonmyeloablative conditioning before hematopoietic cell transplantation.

Oct 23, 2026

Oncology·JCO

End-of-Life Anticancer Therapy Studied in Argentina and Uruguay

Binational multicenter analysis examines systemic anticancer therapy near end of life in Argentina and Uruguay, a key issue…

Oct 23, 2026

Oncology·JCO

Liquid Biopsy MRD in Endometrial and Cervical Cancer Needs Prospective Proof

Liquid biopsy for MRD shows strongest evidence in cervical cancer HPV ctDNA, while endometrial ctDNA remains promising but…

Oct 23, 2026

Oncology·JCO

Tumor Genomics Did Not Replace mFOLFIRINOX as Standard Adjuvant PDAC Therapy

Genomic profiling from PRODIGE-24/CCTG PA6 found prognostic PurIST effects, but no biomarker strong enough to displace mFOLFIRINOX in…

Oct 23, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.